Adverse effects in the treatment of Parkinson’s disease

References

• Lambert D, Waters CH. Comparative tolerability of the newer generation antiparkinsonian agents. Drugs Aging16(1), 55–65 (2000).
   PubMed Web of Science ®Google Scholar
• Krack P Pollak P, Limousin P, Benazzouz A, Deuschl G, Benabid AL. From off-period dystonia to peak-dose chorea. The clinical spectrum of varying subthalamic nucleus activity Brain 122(Pt 6), 1133–1146 (1999).
   Google Scholar
• •This is an outstanding review of the clinical phenomenology of dyskinesias.
   Google Scholar
• Rascol O. The pharmacological therapeutic management of levodopa-induced dyskinesias in patients with Parkinson's disease. J. Neural 247\(Suppl. 2), 1151–57 (2000).
   Google Scholar
• ••This article extensively reviews thepharmacological management of dyskinesias.
   Google Scholar
• Schrag A, Quinn N. Dyskinesias and motor fluctuations in Parkinson's disease. A community-based study. Brain 123(Pt 11), 2297–2305 (2000).
   PubMed Web of Science ®Google Scholar
• Inzelberg R, Carasso RL, Schechtman E, Nisipeanu P. A comparison of dopamine agonists and catechol-O-methyltransferase inhibitors in Parkinson's disease. Gun. Neuropharmacol 23(5), 262–266 (2000).
   PubMed Web of Science ®Google Scholar
• Pinter MM, Pogarell O, Oertel WH. Efficacy, safety and tolerance of the non-ergoline dopamine agonist pramipexole in the treatment of advanced Parkinson's disease: a double-blind, placebo-controlled, randomized, multicentre study. J. Neural Neurosurg. PTchiatty66 (4), 436–441 (1999).
   Google Scholar
• Lieberman A, Olanow CW, Sethi K et al. and the ropinirole Study Group. A multicenter trial of ropinirole as adjunct treatment for Parkinson's disease. Neurology 51,1057–1062 (1998).
   Google Scholar
• Timberlake WH, Vance MA. Four-year treatment of patients with parkinsonism using amantadine alone or with levodopa. Ann. Neural 3(2), 119–128 (1978).
   PubMedGoogle Scholar
• Adler CH, Singer C, O'Brien C et al, for the Tolcapone Fluctuator Study Group III. Randomized, placebo-controlled study of tolcapone in patients with fluctuating Parkinson's disease treated with levodopa-carbidopa. Arch. Neural 55,1089–1095 (1998).
   Google Scholar
• Parkinson Study Group. Pramipexole vs. Levodopa as Initial Treatment for Parkinson's disease. A Randomized Controlled Trial. JAMA 284 (15), 1931-1938 (2000).
   Google Scholar
• Snow BJ, Macdonald L, Mcauley D, Wallis W The effect of amantadine on levodopa-induced dyskinesias in Parkinsoris disease: a double-blind, placebo-controlled study. Gun. Aiumphatmacol 23(2), 82–85 (2000).
   PubMed Web of Science ®Google Scholar
• Jankovic J. Parkinson's disease therapy: tailoring choices for early and late disease, young and old patients. Gun. Neuropharmacol 23(5), 252–261 (2000).
   Google Scholar
• Shannon KM, Bennett JP, Friedman JH for the Pramipexole Study group. Efficacy of pramipexole, a novel dopamine agonist, as monotherapy in mild to moderate parkinon's disease. Neurology 49,724–728 (1997).
   Google Scholar
• Parkinson Study Group. Safety and Efficacy of pramipexole in Early Parkinson's disease. JA /V/A 278,125–130 (1997).
   PubMed Web of Science ®Google Scholar
• Adler CH, Sethi KD, Hauser RA et al, for the ropinirole Study Group. Ropinirole for the treatment of early Parkinson's disease. Neurology 49,393–399 (1997).
   Google Scholar
• Graham JM, Grunewald RA, Sagar HJ. Hallucinosis in idiopathic Parkinson's disease. J. Neural Neurosurg. Psychiatry 63(4), 434–440 (1997).
   Google Scholar
• Montrastuc JL, Chaumerliac C, Desboeuf K et al. Adverse Drug Reactions to Selegiline: A Review of the French Pharmacovigilance Database. Clin. Neuropharm. 23(5), 271–275 (2000).
   PubMedGoogle Scholar
• Young BK, Camicioli R, Ganzini L. Neuropsychiatric Adverse effects of Antiparkinsonian Drugs. Characteristic, Evaluation and treatment. Drugs Aging-10 (5), 367–383 (1997).
   Google Scholar
• •This article reviews the clinical picture and management of neuropsychiatric adverse events.
   Google Scholar
• Molina JA, Sainz-Artiga MJ, Fraile A et al. Pathologic Gambling in Parkinsoris disease: A Behavioral Manifestation of Pharmacologic Treatment? Mov. Disoni 15(5), 869–872 (2000).
   Google Scholar
• Clarenbach P Parkinson's disease and sleep. J. Neural 247\(Suppl. 4), IV/20-23 (2000).
   Google Scholar
• Ferreira JJ, Galitsky M, Montrastuc JL, Rascol O. Sleep attacks and Parkinson's disease treatment. Lancet 353,1333–1334 (2000).
   Google Scholar
• Schafer D, Greulich W Effects of parkinsonian medication on sleep. J. Neural 247\(Suppl. 4), IV/24-27 (2000).
   Google Scholar
• Frucht S, Rogers JD, Greene PE, Gordon ME, Fahn S. Falling asleep at the wheel: motor vehicle mishaps in persons taking pramipexole and ropinirole. Neurology 52(9), 1908–1910 (1999).
   PubMed Web of Science ®Google Scholar
• Brooks DJ, Abbott RJ, Lees AJ et al. A Placebo-Controlled Evaluation of Ropinirole, a Novel D2 Agonist, as Sole Dopaminergic Therapy in Parkinson's disease. Gun. Neumphatmacol 21(2), 101–107 (1998).
   Google Scholar
• Pal S, Bhattacharya KF, Agapito C, Chaudhuri KR. A study of excessive daytime sleepiness and its clinical significance in three groups of Parkinson's disease patients taking pramipexole, cabergoline and levodopa mono and combination therapy. J. Neural. Transm. 108(1), 71–77 (2001).
   Google Scholar
• De& A, Nash J. Falling asleep at the wheel: motor vehicle mishaps in persons taking pramipexole and ropinirole. Neurology 54(1), 275–277 (2000).
   Google Scholar
• Sethi KD, O'Brien CF, Hammerstad JP et al for the Ropinirole Study Group. Awl?. Neural 55,1211–1216 (1998).
   Google Scholar
• Rye DB and Bliwise DL. Falling asleep at the wheel: motor vehicle mishaps in persons taking pramipexole and ropinirole. Neumlogy 54(1), 276–277 (2000).
   PubMedGoogle Scholar
• Hauser RA, Gauger L, Anderson WM, Zesiewicz TA. Pramipexole-induced somnolence and episodes of daytime sleep. Mov. Disarl. 15(4), 658–663 (2000).
   PubMed Web of Science ®Google Scholar
• Hoehn M. Falling asleep at the wheel: motor vehicle mishaps in persons taking pramipexole and ropinirole. Neurology 54(1), 275–277 (2000).
   PubMedGoogle Scholar
• Pirker W, Happe S. Sleep attacks in Parkinson's disease. Lancet 356,597–598 (2000).
   PubMedGoogle Scholar
• Olanow CW, Schapira AHV, Roth T Falling asleep at the wheel: motor vehicle mishaps in persons taking pramipexole and ropinirole. Neurology 54 (1), 274–277 (2000).
   PubMedGoogle Scholar
• Soykan I, Sarovsiek I, Schifflett J, Wooten GF, McCallum RW. Effect of Chronic Oral Domperidone Therapy on Gastrointestinal Symptoms and Gastric Emptying in Patients with parkinson's Disease. Mov. Disoni 12(6), 952–957 (1997).
   Google Scholar
• Cedarbaum JM, Schleifer LS. Drugs for Parkinson's disease, Spasticity and Active Muscle Spasms. In: Goodman and Gilmani The pharmacological Basis of Therapeutics. Eigth Edition. Goodman Gilman A, Rail TW, Nies AS, Taylor P (Eds.). Pergamon Press, Elmsford, New York, USA 463–484 (1990).
   Google Scholar
• Caine DB, Williams AC, Nutt JG, Neophytides A, Eisler T, Teychenne PP. Ergot derivatives for parkinsonism. Med. J. Aust. 2 (Suppl. 3), 25–26 (1978).
   Google Scholar
• Senard JM, Rai S, Lapeyre-Mestre M et al Prevalence of orthostatic hypotension in Parkinson's disease. J. Neural Neurosurg. PFchiatry63(5), 584–589 (1997).
   Google Scholar
• Kujawa K, Leurgans S, Raman R, Blasucci L, Goetz CG. Acute orthostatic hypotension when starting dopamine agonists in Parkinson's disease. Arch. Neural 57(10), 1461–1463 (2000).
   Google Scholar
• Singer C, Weiner WJ, Sanchez-Ramos JR. Autonomic dysfunction in men with Parkinson's disease. Eur. Neural 32,134–140 (1992).
   Google Scholar
• Langtry HD, Clssold SP. Pergolide. A review of its Pharamcological Properties and Therapeutic Potential in Parkinson' Disease. DIM'S 39(3) , 491–506 (1990).
   Google Scholar
• Haapaniemi TH, Kallio MA, Korpelainen JT et al Levodopa, bromocriptine and selegiline modify cardiovascular response in Parkinson's disease. J. Neural 247(11), 868–874 (2000).
   PubMed Web of Science ®Google Scholar
• Lang AE. Acute orthostatic hypotension when starting dopamine agonists in Parkinson's disease. Arch. Neural 58,835 (2001).
   PubMedGoogle Scholar
• Tan EK, Ondo W Clinical characteristics of pramipexole-induced peripheral oedema. Arch. Neural 57(5), 729–732 (2000).
   PubMedGoogle Scholar
• Vollum DI, Parkes JD, Doyle D. Livedo reticularis during amantadine treatment. Br. Med 122(762)627-628 (1971).
   Google Scholar
• Silver DE, Sahs AL. Livedo reticularis in Parkinson's disease patients treated with amantadine hydrochloride. Neurology 22(7), 665–669 (1972).
   PubMedGoogle Scholar
• Parkes JD, Baxter RC, Marsden CD, Rees JE. Comparative trial of benzhexol, amantadine and levodopa in the treatment of Parkinson's disease. J. Neural Neurosurg. PFchiatry37(4), 422–426 (1974).
   Google Scholar
• Blackard WG. Oedema, an infrequently recognized complication of bromocriptine and other ergot dopaminergic drugs. Am J. Med. 94,445 (1993).
   PubMedGoogle Scholar
• Forssman B, Kihlstrand S, Larsson LE. Amantadine therapy in parkinsonism. Acta Neural Scant 48(1), 1–18 (1972).
   PubMedGoogle Scholar
• Wilson TW, Rajput AH. Amantadine- dyazide interaction. Can. Med. Assoc. J. 129(9), 974–975 (1983).
   Google Scholar
• Pearce LA, Waterbury LD, Green HD. Amantadine hydrochloride: alteration in peripheral circulation. Neurology24 (1), 46–48 (1974).
   PubMedGoogle Scholar
• Larrazet F et al Possible bromocriptine- induced myocardial infarction. Ann. Int. Med. 118,199–200 (1993).
   Google Scholar
• Eisler T, Hall RP, Kalavar KAR, Caine DB. Erythromelalgia-like eruption in parkinsonian patients treated with bromocriptine. Neumlogy31, 1368–1370 (1981).
   PubMedGoogle Scholar
• Hillerdal G, Lee J, Blomkvist A et al. Pleural disease during treatment with bromocriptine in patients previously exposed to asbestos. Eur. Respir.J10(12), 2711–2715 (1997).
   Google Scholar
• Shaunak S, Wilkins A, Pilling JB, Dick DJ. Pericardial, retroperitoneal, and pleural fibrosis induced by pergolide. j Neural Neurosurg. fiychiatry66(1), 79–81 (1999).
   Google Scholar
• Knoop C, Mairesse M, Lenclud C, Gevenois PA, De Vuyst R Pleural effusion during bromociptine exposure in two patients with pre-exisiting asbestos pleural plaques: a relationship? Eur Respir1. 10, 2898–2901 (1997).
   Google Scholar
• Camus P, Hillerdal G, De Vuyst R Asbestos, ergot drugs and the pleura. Eur Respir. 11(6), 1427 (1998).
   Google Scholar
• Duvoisin RC. A review of drug therapy in parkinsonism. Buff NY Acad. Med. 41, 898–910 (1965).
   PubMedGoogle Scholar
• Ben-Shlomo Y, Churchyard A, Head J et al. Investigation by Parkinson's disease Research Group of United Kingdom into excess mortality seen in combined levodopa and selegiline treatement in patients with early, mild Parkinson's disease: further results of randomized trial and confidential inquiry. BE Med 316(7139), 1191–1196 (1998).
   Google Scholar
• Aaltonen H, Kilkku O, Heinonen E, Maki- Ikola O. Evidence is insuffucient to show that combined treatment increases mortality. BE Med 317 (7172), 1586–1587 (1998).
   Google Scholar
• Abrams KR. Monitoring randomized clinical trials. Parkinson's disease trial illustrates the dangers of stopping early BE Med 316(7139), 1183–1184 (1998).
   Google Scholar
• Breteler M. Selegiline, or the problem of early termination of clinical trials. The clinical questions are not well answered and probably never will be. BE Med1. 316, 1182–1183 (1998).
   Google Scholar
• Counsell C. Formal systematic review of data on patients in all relevant trials is required. BE Med 317(7172), 1586 (1998).
   Google Scholar
• Siple JF, Schneider DC, Wanlass WA, Rosenblatt BK. Levodopa therapy and the risk of malignant melanoma. Ann. Pharmacother. 34(3), 382–385 (2000).
   PubMedGoogle Scholar
• Pfutzner W Przybilla B. Malignant melanoma and levodopa: is there a relationship? Two new cases and a review of the literature. I A117. Acad. Dermatol 37(2 Pt 2), 332–336 (1997).
   Google Scholar
• Olanow CW and the Tasmar Advisory Panel. Tolcapone and hepatotoxic effects. Arch. Neural 57,263–267 (2000).
   PubMed Web of Science ®Google Scholar
• Spahr L, Rubbia-Brandt L, Burkhard PR, Assal F, Hadengue A. Tokapone-related fulminant hepatitis: electron microscopy shows mitochondrial alterations. Dig. Dis. Sci. 45(9), 1881–1884 (2000).
   Google Scholar
• Iwuagwu CU, Riley D, Bonoma RA. Neuroleptic malignant-like syndrome in an elderly patient caused by abrupt withdrawal of tolcapone, a-catechol-o-methyl transferase inhibitor. Arn Med. 108(6), 517–518 (2000).
   Google Scholar
• Ong KC, Chew EL, Ong YY. Neuroleptic malignant syndrome without neuroleptics. Singapore Med 42(2), 85–88 (2001).
   PubMedGoogle Scholar
• Noveske FG. Breakthrough panic after amantadine treatment in a Parkinsoris disease patient. Clin. Psychiatry57(8), 374 (1996).
   PubMedGoogle Scholar
• Merola B, Sarnacchiaro F, Colao A et al Allergy to ergot-derived dopamine agonists. Lancet 339(8793), 620 (1992).
   PubMedGoogle Scholar